News
Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...
Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a report issued on Tuesday, April 1st. HC Wainwright analyst P. Trucchio now anticipates that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback